ClinicalTrials.gg
CompletedNCT00271817Updated May 16, 2024Results posted

To Evaluate Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) in Patients With Type IIa or Type IIb Hyperlipidemia (0653A-091)(COMPLETED)

A Phase 3 interventional study of Comparator: ezetimibe/simvastatin + niacin (ER) and Comparator: Placebo to ezetimibe/simvastatin in Hypercholesterolemia, sponsored by Organon and Co. Completed. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2024-05-16.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,220
Allocation
Randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 98 studies testing ezetimibe in Hypercholesterolemia — 3 open to participants now, 4 under way, 1 of them phase 3. Ezetimibe · Hypercholesterolemia.

Enrollment
4th of 97
1,220 · median 148
Started
2005
with 13 others
Phase 3
50 of 98
1 open now
Registered
13th of 98
by date
Lead sponsor
55 of 98
Organon and Co

Among the 98 studies testing ezetimibe in Hypercholesterolemia, this one is the 4th largest by enrollment of the 97 interventional ones that give a count, is one of 14 that started in 2005, is one of 50 in phase 3, and was the 13th registered.

Hypercholesterolemia

1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.

Browse Hypercholesterolemia studies →

Open to participants now

3 of the 98 studies testing ezetimibe in Hypercholesterolemia are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About ezetimibe

Ezetimibe: first FDA approval 2002 (ZETIA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies testing ezetimibe in Hypercholesterolemia, or all of them as a file.
02

Study summary

To evaluate the efficacy and safety of ezetimibe/simvastatin and niacin in patients with high cholesterol.

03

Conditions studied

  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with LDL-C of 130 through 190 mg/dL and Triglycerides less than or equal to 500 mg/dL
  • Patient willing to be on a low-cholesterol diet

Exclusion criteria

Exclusion Criteria:

  • Pregnant or lactating women or intending to become pregnant
  • Patient with sensitivity or intolerance to ezetimibe, simvastatin, or ezetimibe/simvastatin combination tablet
  • Patient with sensitivity or intolerance ro niacin, any component or niacin extended release or aspirin
  • Patient for whom discontinuation of existing lipid-lowering therapy treatment poses an unacceptable risk
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,220 participants (actual)

Study arms

  • Active comparator
    Part 1 - Arm 1

    ezetimibe/simvastatin combination tablet + niacin (ER)

    Drug: Comparator: ezetimibe/simvastatin + niacin (ER)

  • Active comparator
    Part 1 -Arm 2

    ezetimibe/simvastatin

    Drug: Comparator: ezetimibe (+) simvastatin · Drug: Comparator: Placebo to Niacin (ER)

  • Active comparator
    Part 1 - Arm 3

    Niacin (ER)

    Drug: Comparator: Placebo to ezetimibe/simvastatin · Drug: Comparator: niacin (ER) tablet

  • Active comparator
    Part 2 - Arm 1

    ezetimibe/simvastatin combination tablet + niacin (ER)

    Drug: Comparator: ezetimibe/simvastatin and niacin (ER)

  • Placebo comparator
    Part 2 - Arm 2

    ezetimibe/simvastatin combination tablet + niacin (Pbo)

    Drug: Comparator: ezetimibe and simvastatin · Drug: Comparator: Placebo to niacin (ER)

Interventions

  • DrugComparator: ezetimibe/simvastatin + niacin (ER)

    Drug pages: Ezetimibe · Simvastatin · Niacin

    ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks

  • DrugComparator: Placebo to ezetimibe/simvastatin

    ezetimibe/simvastatin (Pbo) tablet. Treatment time will be \~24 weeks.

  • niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be \~24 weeks

  • DrugComparator: ezetimibe (+) simvastatin

    ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~24 weeks.

  • DrugComparator: Placebo to Niacin (ER)

    Niacin (ER) (Pbo) tablet. Treatment time will be \~24 weeks.

  • DrugComparator: ezetimibe/simvastatin and niacin (ER)

    Drug pages: Ezetimibe · Simvastatin · Niacin

    ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be \~40 additional weeks for a total of 64 weeks

  • DrugComparator: ezetimibe and simvastatin

    ezetimibe/simvastatin 10/20mg tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks

  • DrugComparator: Placebo to niacin (ER)

    Niacin (ER) (Pbo) tablet. Treatment time will be \~40 additional weeks for a total of 64 weeks

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

    Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change, from baseline in LDL-C after 24 weeks - 24 Week Measure Minus Baseline

    Time frame: Baseline and 24 Weeks

  2. Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

    Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 24 weeks - 24 week measure minus baseline

    Time frame: Baseline and 24 weeks

Secondary outcomes

  1. Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

    Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline

    Time frame: Baseline and 24 weeks

  2. Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)

    Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 24 weeks - 24 week measure minus baseline

    Time frame: Baseline and 24 weeks

  3. Percent Change From Baseline in Triglycerides (TG)

    Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 24 weeks - 24 week measure minus baseline

    Time frame: baseline and 24 Weeks

  4. Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)

    Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 64 weeks - 64 week measure minus baseline

    Time frame: Baseline and 64 weeks

  5. Percent Change From Baseline in Triglycerides (TG)

    Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 64 weeks - 64 week measure minus baseline

    Time frame: Baseline and 64 weeks

  6. Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

    Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 64 weeks - 64 week measure minus baseline

    Time frame: Baseline and 64 weeks

  7. Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

    Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 64 weeks - 64 week measure minus baseline

    Time frame: Baseline and 64 weeks

  8. Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

    Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline

    Time frame: Baseline and 24 weeks

07

Results

Posted Aug 3, 2009
Limitations and caveats
Part 1 population is all patients enrolled in Part 1 of the study. Part 2 is those patients who received either niacin, ezetimibe/simvastatin, or ezetimibe/simvastatin + niacin during Part 1 until they finished the study at week 64 or discontinued.

Participant flow

Part 1
Participant flow — Part 1
MilestoneNiacinEzetimibe/SimvastatinEzetimibe/Simvastatin + Niacin
Started272272676
Completed166213391
Not completed10659285
Withdrew: Adverse event6825156
Withdrew: Lost to follow-up6824
Withdrew: Protocol violation547
Withdrew: Patient moved315
Withdrew: Withdrawal by subject231745
Withdrew: Ldl < 50 mg/dl1448
Part 2
Participant flow — Part 2
MilestoneNiacinEzetimibe/SimvastatinEzetimibe/Simvastatin + Niacin
Started0266485
Completed0234401
Not completed03284
Withdrew: Adverse event01733
Withdrew: Lack of efficacy016
Withdrew: Lost to follow-up0618
Withdrew: Protocol violation035
Withdrew: Patient moved005
Withdrew: Withdrawal by subject0213
Withdrew: Ldl < 50 mg/dl034

Outcome measures

PrimaryPercent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change, from baseline in LDL-C after 24 weeks - 24 Week Measure Minus Baseline

Time frame:
Baseline and 24 Weeks
Reported as:
Mean · Percent change
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
Percent changeNiacinEzetimibe/Simvastatin + Niacin
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)-20.1 ± 1.3-58.5 ± 0.8
Statistical analysis
  • Niacin vs Ezetimibe/Simvastatin + Niacin · ANCOVA · p = <0.001 (A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.) · Mean difference (final values): -38.4 · 95% CI -41.4 to -35.4Mean difference = Ezetimibe/Simvastatin + Niacin minus Niacin
SecondaryPercent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline

Time frame:
Baseline and 24 weeks
Reported as:
Mean · Percent change
Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
Percent changeNiacinEzetimibe/Simvastatin + Niacin
Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)-22.0 ± 1.3-55.6 ± 0.8
Statistical analysis
  • Niacin vs Ezetimibe/Simvastatin + Niacin · ANCOVA · p = <0.001 (A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.) · Mean difference (final values): -33.5 · 95% CI -36.5 to -30.6Mean difference = Ezetimibe/Simvastatin + Niacin minus Niacin
SecondaryPercent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 24 weeks - 24 week measure minus baseline

Time frame:
Baseline and 24 weeks
Reported as:
Mean · Percent change
Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)
Percent changeEzetimibe/SimvastatinEzetimibe/Simvastatin + Niacin
Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)8.1 ± 1.330.2 ± 1.0
Statistical analysis
  • Ezetimibe/Simvastatin vs Ezetimibe/Simvastatin + Niacin · ANCOVA · p = <0.001 (A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.) · Mean difference (final values): 22.1 · 95% CI 18.8 to 25.3Mean difference = Ezetimibe/Simvastatin + Niacin minus Niacin
SecondaryPercent Change From Baseline in Triglycerides (TG)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 24 weeks - 24 week measure minus baseline

Time frame:
baseline and 24 Weeks
Reported as:
Median · Percent change
Percent Change From Baseline in Triglycerides (TG)
Percent changeEzetimibe/SimvastatinEzetimibe/Simvastatin + Niacin
Percent Change From Baseline in Triglycerides (TG)23.7 ± 29.7-42.5 ± 27.5
Statistical analysis
  • Ezetimibe/Simvastatin vs Ezetimibe/Simvastatin + Niacin · ANCOVA · p = <0.001 (A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.) · Median difference (final values): -18.7 · 95% CI -22.6 to -14.7Mean difference = Ezetimibe/Simvastatin + Niacin minus Niacin The median difference is based on the Hodges-Lehmann estimates of shift; The distribution-free 95% CI is based on Wilcoxon's rank sum test statistic.
SecondaryPercent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 64 weeks - 64 week measure minus baseline

Time frame:
Baseline and 64 weeks
Reported as:
Mean · Percent change
Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)
Percent changeEzetimibe/SimvastatinEzetimibe/Simvastatin + Niacin
Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)9.0 ± 1.430.5 ± 1.1
Statistical analysis
  • Ezetimibe/Simvastatin vs Ezetimibe/Simvastatin + Niacin · ANCOVA · p = <0.001 (A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.) · Mean difference (final values): 21.5 · 95% CI 18.0 to 25.0Mean difference = Ezetimibe/Simvastatin + Niacin minus Niacin
SecondaryPercent Change From Baseline in Triglycerides (TG)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 64 weeks - 64 week measure minus baseline

Time frame:
Baseline and 64 weeks
Reported as:
Median · Percent change
Percent Change From Baseline in Triglycerides (TG)
Percent changeEzetimibe/SimvastatinEzetimibe/Simvastatin + Niacin
Percent Change From Baseline in Triglycerides (TG)-26.8 ± 32.7-44.5 ± 26.9
Statistical analysis
  • Ezetimibe/Simvastatin vs Ezetimibe/Simvastatin + Niacin · ANCOVA · p = <0.001 (A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.) · Median difference (final values): -17.6 · 95% CI -21.8 to -13.6Median difference = Ezetimibe/Simvastatin + Niacin minus Ezetimibe/Simvastatin The median difference is based on the Hodges-Lehmann estimates of shift; The distribution-free 95% CI is based on Wilcoxon's rank sum test statistic.
SecondaryPercent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 64 weeks - 64 week measure minus baseline

Time frame:
Baseline and 64 weeks
Reported as:
Mean · Percent change
Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
Percent changeEzetimibe/SimvastatinEzetimibe/Simvastatin + Niacin
Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)-45.1 ± 1.3-52.4 ± 0.9
Statistical analysis
  • Ezetimibe/Simvastatin vs Ezetimibe/Simvastatin + Niacin · ANCOVA · p = <0.001 (A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.) · Mean difference (final values): -7.3 · 95% CI -10.4 to -4.2Median difference = Ezetimibe/Simvastatin + Niacin minus Ezetimibe/Simvastatin
SecondaryPercent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 64 weeks - 64 week measure minus baseline

Time frame:
Baseline and 64 weeks
Reported as:
Mean · Percent change
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
Percent changeEzetimibe/SimvastatinEzetimibe/Simvastatin + Niacin
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)-49.3 ± 1.3-54.0 ± 1.0
Statistical analysis
  • Ezetimibe/Simvastatin vs Ezetimibe/Simvastatin + Niacin · ANCOVA · p = 0.004 (A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.) · Mean difference (final values): -4.8 · 95% CI -8.0 to -1.5Mean difference = Ezetimibe/Simvastatin + Niacin minus Ezetimibe/Simvastatin
PrimaryPercent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 24 weeks - 24 week measure minus baseline

Time frame:
Baseline and 24 weeks
Reported as:
Mean · Percent change
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)
Percent changeEzetimibe/SimvastatinEzetimibe/Simvastatin + Niacin
Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)-53.5 ± 1.2-58.5 ± 0.8
Statistical analysis
  • Ezetimibe/Simvastatin vs Ezetimibe/Simvastatin + Niacin · ANCOVA · p = <0.001 (A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.) · Mean difference (final values): -4.9 · 95% CI -7.7 to -2.1Mean difference = Ezetimibe/Simvastatin + Niacin minus Niacin
SecondaryPercent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline

Time frame:
Baseline and 24 weeks
Reported as:
Mean · Percent change
Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)
Percent changeEzetimibe/SimvastatinEzetimibe/Simvastatin + Niacin
Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)-47.9 ± 1.1-55.6 ± 0.8
Statistical analysis
  • Ezetimibe/Simvastatin vs Ezetimibe/Simvastatin + Niacin · ANCOVA · p = <0.001 (A fixed sequence testing procedure was employed where testing followed a prespecified order and each subsequent hypothesis was tested at the 0.05 level of significance only if all previously tested hypotheses have been rejected.) · Mean difference (final values): -7.7 · 95% CI -10.4 to -5.0Mean difference = Ezetimibe/Simvastatin + Niacin minus Ezetimibe/Simvastatin

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Niacin———
Ezetimibe/Simvastatin———
Ezetimibe/Simvastatin + Niacin———
Ezetimibe/Simvastatin - Part 2———
Ezetimibe/Simvastatin + Niacin - Part 2———
Most frequent serious events
Showing 10 of 66
Most frequent serious events
EventNiacinEzetimibe/SimvastatinEzetimibe/Simvastatin + NiacinEzetimibe/Simvastatin - Part 2Ezetimibe/Simvastatin + Niacin - Part 2
Cerebrovascular AccidentNervous system disorders2/2720/2720/6701/3260/775
Basal Cell CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2720/2720/6702/3262/775
Prostate CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2720/2720/6700/3264/775
OsteoarthritisMusculoskeletal and connective tissue disorders1/2720/2722/6700/3263/775
Breast CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2720/2722/6701/3263/775
SyncopeNervous system disorders0/2720/2722/6700/3263/775
Acute Coronary SyndromeCardiac disorders0/2721/2721/6701/3261/775
Atrial FibrillationCardiac disorders0/2721/2720/6700/3261/775
SpondylolisthesisCongenital, familial and genetic disorders0/2721/2720/6701/3260/775
Chest PainGeneral disorders1/2721/2720/6701/3261/775
Most frequent other events
Showing 10 of 29
Most frequent other events
EventNiacinEzetimibe/SimvastatinEzetimibe/Simvastatin + NiacinEzetimibe/Simvastatin - Part 2Ezetimibe/Simvastatin + Niacin - Part 2
FlushingVascular disorders15/272274/670108/27217/326288/775
PruritusSkin and subcutaneous tissue disorders4/27279/67035/2724/32686/775
Upper Respiratory Tract InfectionInfections and infestations13/27227/6709/27224/32656/775
ArthralgiaMusculoskeletal and connective tissue disorders13/27218/6708/27220/32631/775
DiarrhoeaGastrointestinal disorders9/27227/67010/27212/32647/775
RashSkin and subcutaneous tissue disorders4/27232/67015/2726/32641/775
SinusitisInfections and infestations7/27221/6705/27217/32635/775
ParaesthesiaNervous system disorders2/27225/67014/2724/32629/775
NasopharyngitisInfections and infestations9/27216/6709/27215/32633/775
HeadacheNervous system disorders8/27213/67012/27214/32618/775

Baseline characteristics

Age, Continuous
Age, Continuous(years)NiacinEzetimibe/SimvastatinEzetimibe/Simvastatin + NiacinTotal
Mean56.4 ± 10.657.5 ± 10.356.9 ± 10.956.9 ± 10.7
Sex: Female, Male
Sex: Female, Male(Participants)NiacinEzetimibe/SimvastatinEzetimibe/Simvastatin + NiacinTotal
Female136120352608
Male136152324612
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)NiacinEzetimibe/SimvastatinEzetimibe/Simvastatin + NiacinTotal
Asian1141126
Black13173868
Hispanic14114974
Other3025
White2312405761047
Body Mass Index
Body Mass Index(Participants)NiacinEzetimibe/SimvastatinEzetimibe/Simvastatin + NiacinTotal
<25 kg/m24839135222
25 to <30 kg/m2110119252481
30 to <40 kg/m29794251442
≥ 40 kg/m216193469
No BMI Data1146
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol. 2008 Apr 22;51(16):1564-72. doi: 10.1016/j.jacc.2008.03.003. PubMed 18420099 ↗
  • Le NA, Jin R, Tomassini JE, Tershakovec AM, Neff DR, Wilson PW. Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients. J Am Heart Assoc. 2013 Aug 7;2(4):e000037. doi: 10.1161/JAHA.113.000037. PubMed 23926117 ↗
  • Guyton JR, Fazio S, Adewale AJ, Jensen E, Tomassini JE, Shah A, Tershakovec AM. Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial. Diabetes Care. 2012 Apr;35(4):857-60. doi: 10.2337/dc11-1369. Epub 2012 Feb 14. PubMed 22338103 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2005, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2009, 1 year 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 3, 2006
First posted
Jan 4, 2006
Start
Dec 2005
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Results first posted
Aug 3, 2009
Last update
May 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00271817
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Jan 4, 2006
Start date
Dec 2005
Primary completion
Feb 2008
Completion
Feb 2008
Results posted
Aug 3, 2009
Last update
May 16, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ezetimibe · Simvastatin · Niacin

Start the discussion